News for Trevi Therapeutics, Inc. (TRVI)

A consortium of financial institutions, including Morgan Stanley, Leerink, Stifel, and Cantor Fitzgerald, took on the responsibility of managing the recent offe

PR NewswireNEW HAVEN, Conn., June 3, 2025 NEW HAVEN, Conn., June 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharm

Trevi Therapeutics (TRVI) announces a $100 million public offering at $5.75 per share. Underwriters are granted a 30-day option to purchase up to 2.

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.35% to 42,453.89 while ...

Oppenheimer has increased its price target for Trevi Therapeutics (TRVI) from $20 to $23, maintaining an Outperform rating for the stock. The firm's optimism is

Trevi Therapeutics (TRVI) proposes a $100 million public offering with an additional $15 million option for underwriters. The company is developing Hadu

Trevi Therapeutics, identified by the ticker TRVI, has announced the initiation of a public offering, aiming to raise $100 million through the sale of its commo

Trevi Therapeutics (TRVI) continues to earn the confidence of analysts as D. Boral Capital reaffirms its "Buy" rating on the company. The analysis, delivered by

Trevi Therapeutics (TRVI) announces positive Phase 2b trial results for Haduvio in treating chronic cough in idiopathic pulmonary fibrosis patients. The

Trevi Therapeutics (TRVI) has reported encouraging outcomes from its Phase 2b CORAL trial evaluating Haduvio for managing chronic cough in individuals with idio

Trevi Therapeutics (TRVI) to present topline results from Phase 2b CORAL trial of Haduvio on June 2, 2025. The webcast will provide insights into Haduvi

PR NewswireNEW HAVEN, Conn., May 29, 2025 NEW HAVEN, Conn., May 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharm

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ETCompany ParticipantsJennifer Good - Co-Founder, President and...

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Trevi Therapeutic

U.S. stocks were lower, with the Nasdaq Composite falling around 650 points on Monday. Shares of Redfin Corporation RDFN rose sharply during Monday's session a...

PR NewswireNEW HAVEN, Conn., Feb. 27, 2025 NEW HAVEN, Conn., Feb. 27, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopha

PR NewswireNEW HAVEN, Conn., Feb. 25, 2025 Topline results continue to be expected in the first half of 2025NEW HAVEN, Conn., Feb. 25, 2025 /PRNewswire/ --

Trevi Therapeutics (TRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PR NewswireNEW HAVEN, Conn., Dec. 16, 2024 NEW HAVEN, Conn., Dec. 16, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopha